OGEN: Oragenics Forward P/S Multiple

Public company logo of Oragenics, Inc. (OGEN)

The change in forward P/S illustrates the valuation dynamics of Oragenics, Inc. (OGEN), where the 372.50 mark reflects the current state. The current trend is driven by capital expenditure on R&D in the absence of regular sales. However, the diversification of developments against various strains mitigates investment risks. Its status as an authoritative creator of intranasal drugs strengthens the medical community's confidence in the company's potential.

OGEN Oragenics: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/15/2024

Analytical breakdowns for Oragenics, Inc.

- stock price and consensus target price:
Stock Quotes Oragenics, Inc.|OGEN - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Oragenics, Inc.|OGEN - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Oragenics|OGEN - Total Stockholders' Equity|Market Value to Book Value Ratio oragenics.com|OGEN - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity Oragenics, Inc.|OGEN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Oragenics|OGEN - Company Cumulative Debt|Debt to Book Capitalization Ratio Oragenics, Inc.|OGEN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Oragenics|Quick Ratio oragenics.com
- business earnings and investment ratios data:
OGEN - Annual Net Income|Projected Future Earnings Oragenics, Inc.|OGEN - Market Cap to Earnings|Future Price to Earnings Oragenics, Inc.|OGEN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Oragenics, Inc.|OGEN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Oragenics|OGEN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months oragenics.com|OGEN - Expected net earnings per share growth this year|Expected earnings per share growth for next year Oragenics, Inc.
- revenue and sales details:
OGEN - Company Sales Revenue|Projected Sales Volume Oragenics|OGEN - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Oragenics, Inc.
Initial company analysis:OGEN (Oragenics, Inc.)
Original product of Oragenics

Since Oragenics, Inc. (OGEN) is in the R&D stage and is entirely dependent on external capital, its valuation is driven exclusively by future expectations. The current forward P/S level illustrates the market's reaction to borrowing costs and revenue forecasts, capturing the expansion or contraction of investment horizons for this venture security, where any extremes signal a high risk of correction.

Key competitors

Summit Therapeutics Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio MRNA (Moderna Inc)|Vaxcyte Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Tarsus Corp TARS|CorMedix Inc. (CRMD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio serestherapeutics.com (MCRB)|Price-to-Projected Revenue Ratio Spero Therapeutics, Inc.|Market Cap to Projected Revenue SCYX (Scynexis)|Price-to-Projected Revenue Ratio AN2 Therapeutics, Inc. (ANTX)|Market Cap to Expected Sales Ratio polypid.com|Price-to-Projected Revenue Ratio LakeShore Biopharma Co. LSB|Iterum Therapeutics PLC (ITRM) - Market Cap to Future Revenue Ratio|PHGE - Price-to-Projected Revenue Ratio|Forward Price to Sales SNGX (Soligenix, Inc.)|SXTP: Forward P/S Multiple|OpGen Corporation (OPGN) - Forward P/S Multiple